Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Cue Biopharma Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cognition Therapeutics Inc. June 17, 202695.7%
-
Actuate Therapeutics Inc. May 21, 202688.8%
-
Cognition Therapeutics Inc. June 9, 202395.4%
-
Cue Biopharma Inc. June 7, 202382.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 19, 2025 | Cognition Therapeutics Inc. | Option exercise | +7,729 | $0.84 | $6,492 |
| May 24, 2024 | Lantern Pharma Inc. | Open-market sale | −1,859 | $6.33 | $11,767 |
| May 24, 2024 | Lantern Pharma Inc. | Open-market sale | −13,888 | $6.33 | $87,911 |
| May 24, 2024 | Lantern Pharma Inc. | Open-market sale | −4,253 | $6.33 | $26,921 |
| May 23, 2024 | Lantern Pharma Inc. | Open-market sale | −930 | $6.25 | $5,813 |
| May 23, 2024 | Lantern Pharma Inc. | Open-market sale | −6,944 | $6.25 | $43,400 |
| May 23, 2024 | Lantern Pharma Inc. | Open-market sale | −2,126 | $6.25 | $13,288 |
| Nov 29, 2023 | Lantern Pharma Inc. | Open-market sale | −53,640 | $3.44 | $184,522 |
| Nov 29, 2023 | Lantern Pharma Inc. | Open-market sale | −91,708 | $3.44 | $315,476 |
| Nov 8, 2023 | Cognition Therapeutics Inc. | Grant or award | +500,095 | $1.05 | $525,100 |
Questions about Aaron G.l. Fletcher
What boards is Aaron G.l. Fletcher on?
Aaron G.l. Fletcher sits on the boards of Actuate Therapeutics Inc., Cognition Therapeutics Inc. and Cue Biopharma Inc.
How long has Aaron G.l. Fletcher served on boards?
Our records show at least 10 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.